Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Docs & Patients Should Remember to Use Generics

Kathryn Doyle  |  November 24, 2015

(Reuters Health)—Prescribing generic medicines instead of brand name drugs whenever possible cuts costs, improves patient adherence and improves health outcomes, according to a new recommendation from the American College of Physicians.

“Generic medications are cheaper and patients are more likely to get those prescriptions filled,” says Dr. Amir Qaseem of the American College of Physicians, who coauthored the recommendation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This is for both physicians and patients,” Dr. Qaseem told Reuters Health by phone.

Despite what some patients and even doctors may believe, generics are consistently as effective and safe as their brand-name counterparts, he says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACP reviewed existing evidence and found that for Medicare beneficiaries with diabetes, for example, up to 45% of prescriptions are for brand-name drugs when identical generics are available. Choosing these generics instead, and choosing therapeutically similar but chemically different generics in some other cases, could save up to $1.4 billion for Medicare, the reviewers found.

Brand name prescriptions are almost twice as likely to be prescribed but never picked up from the pharmacy than generics, and not adhering to prescribed medications leads to higher out-of-pocket costs for patients later on, the reviewers wrote online Nov. 23 in the Annals of Internal Medicine.

“Often, patients don’t tell their doctors they can’t afford an expensive drug they were prescribed; they just fail to take it, or take it at sub-therapeutic (too low) doses because of its cost,” says Dr. Jerome Avorn, professor of medicine at Harvard Medical School in Boston, who was not part of the new study. “And this has major health effects.”

“Logically it might feel like people should already be using (generics), but that’s not the case,” Dr. Qaseem says.

The new recommendation “is based on a thorough review of data from a huge number of relevant studies in the medical literature, raising it above the level of ‘conventional wisdom,'” Dr. Avorn says.

The American College of Physicians is one of the most widely respected bodies in medicine, Dr. Avorn told Reuters Health by email.

Some physicians may not be aware that a generic form of a medication is available, or may refer to the drug by its brand name out of habit, which results in more expensive prescriptions, Dr. Qaseem says.

Continuing physician education programs could keep doctors abreast of available generics, as well as interactive options on electronic health records, he says.

“A large scale public awareness campaign is what’s needed,” he says. “Many think if it’s cheaper it’s not as good.”

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:American College of Physiciansgeneric drugsMedicarerecommendation

Related Articles

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    As Drug Prices Drop, Generics Makers Fight Back with Deals

    July 27, 2017

    NEW YORK (Reuters)—Generic drug makers are turning to mergers and acquisitions to shield themselves against a concerted effort by U.S. regulators to crack down on steep drug prices. Impax Laboratories Inc, Perrigo Company Plc and Alvogen Inc have been talking to advisers about strategic options for their generics businesses, ranging from acquisitions to increase scale…

    Pharmacists Not Required to Substitute Generics for Brand-Name Drugs in Most U.S. States

    September 1, 2020

    (Reuters Health)—Only 19 U.S. states mandate that pharmacists fill prescriptions for brand-name small molecule drugs with generics when available, with the 31 remaining states allowing but not requiring these substitutions, a new study finds. Researchers examined laws on the books as of September 2019 pertaining to generic substitution of small molecule drugs, as well as…

    Rheumatologists Struggle with Drug Shortages

    October 7, 2011

    While not yet at a ‘catastrophic’ level, shortages are becoming more common

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences